KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Long-Term Debt Issuances (2016 - 2024)

Gilead Sciences filings provide 11 years of Long-Term Debt Issuances readings, the most recent being $3.5 billion for Q4 2024.

  • On a quarterly basis, Long-Term Debt Issuances rose 346300.0% to $3.5 billion in Q4 2024 year-over-year; TTM through Dec 2024 was $3.5 billion, a 247.89% increase, with the full-year FY2024 number at $3.5 billion, up 74.95% from a year prior.
  • Long-Term Debt Issuances hit $3.5 billion in Q4 2024 for Gilead Sciences, up from $1.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $3.5 billion in Q4 2024 to a low of $1.0 million in Q4 2023.
  • Median Long-Term Debt Issuances over the past 3 years was $995.0 million (2020), compared with a mean of $1.5 billion.
  • The widest YoY moves for Long-Term Debt Issuances: up 346300.0% in 2024, down 346300.0% in 2024.
  • Gilead Sciences' Long-Term Debt Issuances stood at $995.0 million in 2020, then crashed by 99.9% to $1.0 million in 2023, then surged by 346300.0% to $3.5 billion in 2024.
  • The last three reported values for Long-Term Debt Issuances were $3.5 billion (Q4 2024), $1.0 million (Q4 2023), and $995.0 million (Q4 2020) per Business Quant data.